SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: August 18, 1999
MEDIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-19131
Delaware 52-1555759
(State of Incorporation) (I.R.S. Employer Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive office (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
No Exhibits are being filed with this report
CytoGam and RespiGam are registered trademarks of the Company and Synagis is a
trademark.
<PAGE>
MEDIMMUNE, INC.
Current Report on Form 8-K
ITEM 5. OTHER EVENTS
MedImmune, Inc. reported the information contained in the following press
release dated August 17, 1999:
MEDIMMUNE APPOINTS ARMANDO ANIDO, R.PH. SENIOR VICE PRESIDENT
OF SALES AND MARKETING
Gaithersburg, MD, August 17, 1999 -- MedImmune, Inc. (Nasdaq: MEDI) today
announced that Armando Anido, R.Ph. has joined the Company as Senior Vice
President of Sales and Marketing. Mr. Anido will report to Melvin D. Booth,
President and Chief Operating Officer of MedImmune, and will be responsible for
all aspects of the Company's sales and marketing organization, including
oversight of the sales force, development of novel marketing strategies and
medical affairs. Mr. Anido was most recently Vice President of CNS Marketing at
Glaxo Wellcome, Inc. (NYSE: GLX) and prior to that served six years at Lederle
Laboratories, including as Vice President of Anti-Infectives Marketing.
"As MedImmune continues its exciting growth phase and enters into the second
season launch of Synagis, it is essential that the sales and marketing
organization continues its high level of performance," commented Melvin D.
Booth, President and Chief Operating Officer. "Armando brings to MedImmune an
expertise in successfully directing the launch and development of pharmaceutical
products, and was instrumental in growing the Glaxo Wellcome CNS business by
over $950 million in two years. His experience will enhance our ability to excel
in marketing and the entrepreneurial biotechnology environment, and I am
delighted to welcome him to the Company."
While serving as Vice President of CNS Marketing at Glaxo Wellcome, Mr. Anido
had profit and loss responsibility for a CNS business that exceeded $1.8 billion
in 1998. He managed the CNS marketing team and was directly responsible for the
launches of seven products/line extensions within 24 months. Additionally, he
directed the launch of Epivir (R), a successful HIV product with sales of over
$260 million in the first year. Prior to joining Glaxo Wellcome, Inc., Mr. Anido
served in various positions at Lederle Laboratories from 1989 to 1995,
culminating in his service as the Vice President of Anti-Infectives Marketing.
At Lederle Laboratories, he directed the development, launch and implementation
of two successful pharmaceutical marketing plans for ZOSYN (R), a broad spectrum
IV antibiotic and the PROSTEP (R) nicotine patch. From 1985 to 1989, Mr. Anido
served as the Senior Director of Marketing for Martec Pharmaceutical, Inc. Prior
to 1985, he served in various sales positions at the Upjohn Company. Mr. Anido
is a registered pharmacist, and holds a Bachelor of Science and a Master of
Business Administration degree from West Virginia University.
Mr. Anido will replace Mr. David P. Wright, the Executive Vice President of
Sales and Marketing at MedImmune, who is retiring.
"David Wright has been a key officer in building MedImmune to where it is today,
and we will always be grateful to him for the value he has added to the
Company," said Wayne T. Hockmeyer, Ph.D., Chairman and Chief Executive Officer
at MedImmune. "Dave was directly responsible for many of the successes we have
enjoyed at MedImmune, including the successful launch and marketing of Synagis,
one of the most successful pediatric product launches in history. His insight
and effectiveness as a marketing strategist has been clearly demonstrated
throughout his career at MedImmune, and we all wish him well in his retirement."
<PAGE>
Synagis is a humanized monoclonal antibody which was approved for marketing in
June 1998 by the U.S. Food and Drug Administration for the prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of RSV disease (please see full prescribing information attached or at
http://www.medimmune.com/products/synagispi.htm). Synagis is the first
monoclonal antibody to be licensed for any infectious disease. Synagis is
administered by intramuscular injection once per month during anticipated
periods of RSV prevalence in the community. RSV is the most common cause of
pneumonia and bronchiolitis in infants and children. In the Northern Hemisphere,
the RSV season typically commences in November and lasts through April but it
may begin earlier or persist later in certain communities.
MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease, transplantation medicine, autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based sales force and has
five new product candidates in clinical trials.
This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions. Actual
results could differ materially from those currently anticipated as a result of
a number of factors, including risks and uncertainties discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
MEDIMMUNE, INC.
(REGISTRANT)
BY (SIGNATURE) /s/ David M. Mott
(NAME AND TITLE) David M. Mott, Vice Chairman and
Chief Financial Officer
(DATE) August 17, 1999
